FDA
-
-
-
-
-
-
-
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
-
-
-
-
-
-
-
Wolfe Research Starts Mirum Pharmaceuticals (MIRM) at Outperform
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
-
-
-
-
-
-
-
Mirum Pharmaceuticals completes Bluejay acquisition for hepatitis drug
-
-
-
-
-
-
-
Morgan Stanley: 'we view the HDV program as promising and we view the transaction as a good fit for Mirum'
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
-
330,132 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

